Skip to main content
. Author manuscript; available in PMC: 2018 Jan 2.
Published in final edited form as: Mucosal Immunol. 2017 Apr 12;11(1):120–130. doi: 10.1038/mi.2017.31

Figure 4. Inhibition of mitochondria ROS effects attenuates and promotes recovery from colitis:

Figure 4

(a) Experimental protocol of 4-week colonic administration of rotenone vs. vehicle vs. MQ (3x/week) in mdr1a-/- with established chronic colitis. (b) Stool consistency measurements in rotenone vs. vehicle treated vs. MQ in mdr1a-/- at weekly intervals. (c) Histology colitis scores of rotenone vs. vehicle vs. MQ vs. non-colitic mdr1a-/- mice. (d) Representative whole colons and spleen sizes of and H&E of rotenone vs. vehicle vs. MQ vs. non-colitic mdr1a-/- mice. (e) Experimental protocol of colonic MQ vs. vehicle – 3x administrations during 7-day 2% DSS colitis protocol. (f, g) Daily percentages change from initial weight clinical colitis in MQ vs. vehicle in mdr1a-/- (n=6/group) and and WT mice (n=6/group) respectively. (h) Histology colitis scores in MQ vs. vehicle treated mdr1a-/- and WT mice, scale bar 50µm. (i) Experimental protocol of colonic MQ vs. vehicle treatment after 5 days of 2% DSS colitis protocol in WT mice. (j) Daily percentages of change from initial weight in MQ vs. vehicle treated WT, (n=8/7 respectively). All data represent mean± SEM.